Fulgent Genetics, Inc.
FLGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | -0.12 | -0.12 | 0.40 |
| FCF Yield | 0.73% | -6.04% | -1.76% | 3.75% |
| EV / EBITDA | -84.64 | -34.47 | -79.80 | -52.24 |
| Quality | ||||
| ROIC | -0.54% | -1.56% | -1.76% | -1.08% |
| Gross Margin | 42.24% | 42.10% | 38.59% | 41.79% |
| Cash Conversion Ratio | -1.63 | 1.57 | 0.37 | -4.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.28% | -0.45% | -7.11% | -22.92% |
| Free Cash Flow Growth | 113.67% | -304.38% | -143.07% | 160.61% |
| Safety | ||||
| Net Debt / EBITDA | 17.16 | 5.21 | 10.19 | 4.69 |
| Interest Coverage | 243.79 | -1,159.59 | -1,413.93 | -76.83 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 5.27 | 0.00 | 0.00 |
| Cash Conversion Cycle | 42.68 | 74.73 | 51.19 | 53.71 |